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Klotho is a putative aging suppressor gene encoding a
single-pass transmembrane co-receptor that makes the
fibroblast growth factor (FGF) receptor specific for FGF-23.
In addition to multiple endocrine organs, Klotho is expressed
in kidney distal convoluted tubules and parathyroid cells,
mediating the role of FGF-23 in bone–kidney–parathyroid
control of phosphate and calcium. Klotho
–/– mice display
premature aging and chronic kidney disease-associated
mineral and bone disorder (CKD-MBD)-like phenotypes
mediated by hyperphosphatemia and remediated by
phosphate-lowering interventions (diets low in phosphate or
vitamin D; knockouts of 1a-hydroxylase, vitamin D receptor,
or NaPi cotransporter). CKD can be seen as a state of
hyperphosphatemia-induced accelerated aging associated
with Klotho deficiency. Humans with CKD experience
decreased Klotho expression as early as stage 1 CKD; Klotho
continues to decline as CKD progresses, causing FGF-23
resistance and provoking large FGF-23 and parathyroid
hormone increases, and hypovitaminosis D. Secreted Klotho
protein, formed by extracellular clipping, exerts FGF-23-
independent phosphaturic and calcium-conserving effects
through its paracrine action on the proximal and distal
tubules, respectively. We contend that decreased Klotho
expression is the earliest biomarker of CKD and the
initiator of CKD-MBD pathophysiology. Maintaining normal
phosphate levels with phosphate binders in patients with
CKD with declining Klotho expression is expected to reduce
mineral and vascular derangements.
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Klotho, named after an ancient Greek goddess of fate, is a
putative aging suppressor gene. A defect in Klotho gene
expression in mice confers penetrant phenotypes resembling
human premature aging syndromes,
1 whereas Klotho over-
expression confers longevity exceeding the wild type.
2
Pathology in Klotho
–/– mice includes osteopenia and calciﬁca-
tions (vascular and ectopic) resembling chronic kidney disease-
associated mineral and bone disorder (CKD-MBD), in addition
to short lifespan and senescent changes in the heart, lungs,
thymus, gonads, skin, muscles, hearing, and motor neurons
(reviewed by Kuro-o
3). The Klotho gene encodes a single-pass
transmembrane protein expressed predominantly in the
kidney (intensely in the distal convoluted tubule (DCT)
and to a lesser extent in the proximal tubule
1,3,4) and
parathyroid gland.
5
The phenotypes of Klotho
–/– and Fgf23
–/– mice are very
similar, involving premature aging and abnormal mineral
metabolism.
1,6 Both mutants share the senescent phenotypes
of short lifespan, growth retardation, hypogonadism, early
thymic involution, skin and muscle atrophy, osteoporosis,
and emphysema, and deranged mineral metabolism pheno-
types including vascular calciﬁcation, hyperphosphatemia,
hypercalcemia, hypoglycemia, and hypervitaminosis D. These
similarities point to the involvement of Klotho and ﬁbroblast
growth factor (FGF)-23 in a common physiological pathway.
OBJECTIVE
This review article will discuss the involvement of Klotho in
phosphate metabolism in CKD-MBD and propose the
hypothesis that Klotho deﬁciency is the earliest biomarker
of CKD.
THE KLOTHO PROTEIN AS OBLIGATE FGF-23 CO-RECEPTOR
Canonical FGF receptors (FGFRs), which require cofactors
for speciﬁc binding and signal transduction, are expressed
in multiple tissues. Most FGFs use heparan sulfate as a
cofactor facilitating their binding to FGFRs.
3 Endocrine
FGFs, however, including FGF-23, use other cofactors
(or co-receptors).
3 Klotho protein is a co-receptor speciﬁc
for FGF-23 (refs 7, 8).
Kidney
1 and parathyroid
5 Klotho expression identiﬁes
these organs as high-afﬁnity FGF-23 endocrine targets. The
Klotho/FGFR complex thus mediates FGF-23 participation in
the bone–kidney–parathyroid endocrine axis. In the kidney,
FGF-23 acting on Klotho/FGFR suppresses phosphate
reabsorption and 1,25(OH)2D3 synthesis;
9 in the parathyroid,
FGF-23 suppresses parathyroid hormone secretion,
5,10,11
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1,25(OH)2D3 synthesis. Thus, FGF-23 is both a phosphaturic
hormone and the counter-regulatory hormone to vitamin D
in the bone–kidney–parathyroid endocrine axis, and Klotho is
required for the effects of FGF-23 (ref. 12; Figure 1). Both
these FGF-23 actions promote negative phosphate balance.
Thus, FGF-23 can be identiﬁed as ‘phosphatonin’, the bone-
generated humoral phosphaturic factor postulated more than
10 years ago.
13 Secretion of FGF-23 by bone is induced by
phosphate and 1,25(OH)2D3(9) and possibly by parathyroid
hormone.
10,14 Klotho gene expression is inducible by
1,25(OH)2D3 (ref. 15).
PATHOGENESIS OF HYPERPHOSPHATEMIA IN
KLOTHO
–/– MUTANTS
Phosphate pathophysiology mediates complex aging-like
phenotypes in mice with defects in the Klotho–FGF-23
system. Low-phosphate diet improves the aging-like pheno-
types of Klotho mutant mice
16 and Fgf23
–/– mice.
17 Mutant
homozygotes consuming 1.03g phosphorus/100g diet had
typical mutant phenotypes. Male homozygotes consuming
0.4g phosphorus/100g diet expressed the Klotho protein in
their kidneys and resumed normal spermatogenesis.
16 Female
homozygotes required zinc supplementation as well as
phosphorus restriction for phenotypic rescue.
16 Phosphate
restriction corrected CKD-MBD-like FGF-23-null pheno-
types (hyperphosphatemia, vascular calciﬁcations, and
mortality) even though serum calcium and 1,25(OH)2D3
levels remained elevated.
17 Several other genetic and dietary
interventions that rescue Klotho
–/– and/or Fgf23
–/– pheno-
types
18–20 have lowered serum phosphate as their only
common denominator (Table 1). Phosphate retention may
thus accelerate aging and/or age-related diseases in mice and
humans.
21
Patients with CKD are far more likely to die of
cardiovascular disease than to live to require dialysis.
22
CKD-related cardiovascular disease is substantially fueled by
hyperphosphatemia and can be seen as phosphate-related
accelerated cardiovascular aging.
23
A KLOTHO-CENTRIC VIEW OF CKD
It may be hypothesized that CKD represents a state of
accelerated aging associated with Klotho deﬁciency and
phosphate retention, and that Klotho deﬁciency is the earliest
biomarker of CKD and the initiator of CKD-related mineral
dysregulation.
Klotho expression declines progressively in CKD as
FGF-23 expression increases progressively; high serum phos-
phate and parathyroid hormone and low 1,25(OH)2D3
accompany these changes (Figure 2). The ﬁrst measurable
decline in urinary secreted Klotho expression (as detected by
western blotting of concentrated urine samples, normalized
to the same creatinine content) occurs as early as stage 1
CKD
24 and is potentially an early clinical marker of nascent
acute renal damage. Klotho decline precedes FGF-23 increase
as CKD develops in Jck mice, a cystic kidney disease model of
early progressive CKD.
25 Renal Klotho expression assays
(mRNA measurement by RNAse protection, protein mea-
surement by western blotting, and immunohistochemistry)
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Figure 1|Endocrine regulation of phosphate metabolism.
Circulating 1,25(OH)2D3 turns on the FGF-23 promoter in bone
cells. Secreted FGF-23 binds to renal cell Klotho/FGF receptor
to turn off the 1a-hydroxylase promoter and turn on the
24-hydroxylase promoter, resulting in net inactivation of
conversion of vitamin D to 1,25(OH)2D3. PTH affects these renal
promoters in a reverse manner to FGF-23, leading to 1,25(OH)2D3
production. In the parathyroid, FGF-23 binds to Klotho/FGF
receptor and shuts off the PTH promoter. FGF-23, fibroblast
growth factor-23; PTH, parathyroid hormone.
Table 1|Effects on mineral metabolism of interventions
rescuing Klotho
–/– and Fgf23
–/– mouse phenotypes
17–20
Direction of change in serum levels
Intervention Phosphate 1,25(OH)2D3 Calcium
Low-phosphate diet km m
1a-Hydroxylase knockout kk k
Vitamin D receptor knockout km k
Na–Pi cotransporter IIa knockout km m
Low-vitamin D diet kk k
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Figure 2|Changes in Klotho protein, FGF-23, PTH,
1,25(OH)2D3, and phosphate as CKD progresses. When Klotho
expression first decreases, FGF-23 increases, lowering circulating
1,25(OH)2D3, which depresses Klotho expression further and
increases PTH expression. Increased PTH induces further FGF-23
increases, causing large decreases in 1,25(OH)2D3 and large
increases in PTH. This cycle results in hyperphosphatemia in
late stages of CKD. CKD, chronic kidney disease; FGF-23, fibroblast
growth factor-23; PTH, parathyroid hormone.
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showed that dialysis patients expressed renal membrane
Klotho at only 5–15%, most often o5%, of control levels.
26
Median Klotho mRNA levels in healthy kidney tissue
represented slightly 48% of the level of glyceraldehyde-
3-phosphate dehydrogenase, a housekeeping mRNA.
26 A
sandwich enzyme-linked immunosorbent assay for secreted
Klotho in serum also exists and has shown that circulating
secreted Klotho in healthy adults ranges from 239 to 1266pg/
ml, decreasing with advancing age and increasing calcemia
and increasing with phosphatemia levels.
27 More sensitive
assays by multiple reaction monitoring using mass spectro-
metry are currently in progress.
Reducing serum FGF-23 increases serum 1,25(OH)2D3
and renal Klotho expression. Parathyroidectomy is expected
to reduce FGF-23 production,
14 which in turn increases
1,25(OH)2D3 synthesis and then renal Klotho expression.
Vitamin D administration,
15 peroxisome proliferator-acti-
vated receptor-g agonists,
28 or angiotensin II inhibitors
29,30
also increase Klotho expression.
Large serum FGF-23 increases during CKD progression
31
are efforts to maintain FGF-23 signaling as receptor
availability decreases. In the normal kidney, Klotho expres-
sion is abundant and a small amount of FGF-23 effectively
induces phosphaturia. As CKD progresses, ever-increasing
serum FGF-23 acts on a resistant kidney with ever-fewer
functional nephrons, each of which expresses less Klotho than
in a healthy kidney. Serum FGF-23 increases in an attempt
to maintain normophosphatemia, but also suppresses
1,25(OH)2D3 synthesis.
31 Ultimately, total phosphate excretion
can no longer keep pace and serum phosphate increases.
Klotho is a renoprotective factor; when overexpressed it
exerts a beneﬁcial effect on mouse glomerulonephritis
32 and
acute kidney injury
33 models. Decline in renal Klotho expres-
sion precedes both FGF-23 overexpression and hyperpho-
sphatemia, and may represent the initiating event of CKD.
Thus far, we have discussed modulation of the bone–-
kidney–parathyroid endocrine and phosphaturic axis by renal
and parathyroid cell-surface Klotho. However, Klotho also
exists as a secreted form produced by clipping the
extracellular part of the molecule.
34,35 No form of Klotho
protein without FGFR can bind to FGF-23 with high afﬁnity.
Secreted Klotho is found in blood, urine, and cerebrospinal
ﬂuid,
36 and acts as an FGF-23-independent phosphaturic
hormone.
4
SECRETED KLOTHO, PHOSPHATE EXCRETION, AND RENAL
PARACRINE SIGNALING
Proximal tubules are where FGF-23 suppresses phosphate
reabsorption and 1,25(OH)2D3 synthesis. However, Klotho is
expressed most intensely in renal DCT and only weakly
in proximal tubules. Two mechanisms for proximal tubule
FGF-23 activity are possible:
3 either FGF-23 acts directly on
the proximal tubules and Klotho’s function in the DCT is
unexplained, or FGF-23 acts through Klotho on the DCT to
induce a paracrine signal to proximal tubules.
37
The extracellular portion of Klotho protein is clipped by
membrane proteases ADAM10 and ADAM17 (ref. 34) and
BACE1 (ref. 35) and secreted into blood, urine, and
cerebrospinal ﬂuid.
36 Secreted Klotho inhibits the sodium/
phosphate transporters NPT2a, NPT2c, and NPT3 (refs 4,
24) and activates ion channels TRPV5 (ref. 38), TRPV6
(ref. 39), and ROMK1 (ref. 40).
Secreted Klotho exerts phosphaturic effects independently
of FGF-23. Intravenously administered secreted Klotho
induces phosphaturia in normal and Fgf23
–/– mice.
4 NaPi2a
mediates proximal tubule phosphate reabsorption (70–80%
of total phosphate reabsorption); studies on brush border
membrane vesicles from proximal tubule cells show that
secreted Klotho inactivates NaPi2a.
4
Secreted Klotho conserves serum calcium and reduces
calciuria. Some 70% of calcium reabsorption occurs in the
proximal tubule and 15% in the DCT (utilizing TRPV5;
ref. 41). Whole-cell patch-clamp experiments show that secreted
Klotho activates the calcium channel TRPV5 (ref. 38), which is
responsible for DCT calcium reabsorption.
41
We hypothesize that FGF-23 suppresses renal phosphate
reabsorption and promotes calcium reabsorption by promot-
ing the secretion of Klotho from DCT cells. Klotho entering
the luminal ﬂuid inhibits NaPi2a in proximal tubules to allow
phosphate excretion and activates TRPV5 in distal tubules to
reabsorb calcium. Secreted Klotho is present in the luminal
ﬂuid of proximal tubules,
4 but how it is transported into the
proximal tubular lumen is not yet known.
CONCLUSIONS
Renal and parathyroid Klotho co-receptors make FGFR
speciﬁc for FGF-23, the humoral phosphatonin secreted by
bone. In the kidney, Klotho mediates phosphate excretion
and feedback inhibition of 1,25(OH)2D3 synthesis in
response to FGF-23. Klotho deﬁciency causes hyperpho-
sphatemia and accelerated aging phenotypes, which are
prevented in animals by resolving phosphate retention.
CKD and its complications, including CKD-MBD and
vascular calciﬁcation, represent accelerated aging triggered by
Klotho deﬁciency. Klotho expression begins declining early in
CKD and may precede both hyperphosphatemia and FGF-23
upregulation. Further research is needed to determine
whether Klotho decline or increased FGF-23 drives the
vicious cycle of phosphate pathology in CKD.
Secreted Klotho, an FGF-23-independent phosphaturic
hormone, regulates renal sodium/phosphate cotransporters
and calcium and potassium ion channels. We hypothesize
that FGF-23 induces secretion of Klotho from DCT cells, and
secreted Klotho is a paracrine signal to proximal tubule cells
to inhibit phosphate reabsorption and stimulate calcium
reabsorption. Decreased urinary secreted Klotho may reﬂect
decreased renal Klotho expression and is one of the earliest
biomarkers of CKD.
It is concluded that phosphate retention induces complex
aging-like phenotypes. Thus, maintaining normal phosphate
levels with phosphate binders in patients with CKD with
S22 Kidney International (2011) 79 (Suppl 121), S20–S23
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and vascular derangements.
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